新型抗菌剂 PRF-119（一种重组嵌合噬菌体溶菌素）对金黄色葡萄球菌的体外活性。
In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.
机构信息
University Hospital of Münster, Institute of Medical Microbiology, D-48149 Münster, Germany.
出版信息
Antimicrob Agents Chemother. 2011 Sep;55(9):4416-9. doi: 10.1128/AAC.00217-11. Epub 2011 Jul 11.
Abstract
Antistaphylococcal activity of the novel chimeric endolysin PRF-119 was evaluated with the microdilution method. The MIC(50) and MIC(90) of 398 methicillin-susceptible Staphylococcus aureus isolates were 0.098 μg/ml and 0.391 μg/ml, respectively (range, 0.024 to 0.780 μg/ml). Both the MIC(50) and MIC(90) values of 776 methicillin-resistant S. aureus isolates were 0.391 μg/ml (range, 0.024 to 1.563 μg/ml). All 192 clinical isolates of coagulase-negative staphylococci exhibited MIC values of >50 μg/ml. In conclusion, PRF-119 exhibited very good activity specifically against S. aureus.
摘要
采用微量稀释法评估了新型嵌合内溶素 PRF-119 的抗葡萄球菌活性。398 株甲氧西林敏感金黄色葡萄球菌分离株的 MIC50 和 MIC90 分别为 0.098μg/ml 和 0.391μg/ml（范围为 0.024 至 0.780μg/ml）。776 株耐甲氧西林金黄色葡萄球菌分离株的 MIC50 和 MIC90 值均为 0.391μg/ml（范围为 0.024 至 1.563μg/ml）。所有 192 株凝固酶阴性葡萄球菌的临床分离株 MIC 值均>50μg/ml。总之，PRF-119 对金黄色葡萄球菌具有非常好的活性。
相似文献
1
In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.新型抗菌剂 PRF-119（一种重组嵌合噬菌体溶菌素）对金黄色葡萄球菌的体外活性。
Antimicrob Agents Chemother. 2011 Sep;55(9):4416-9. doi: 10.1128/AAC.00217-11. Epub 2011 Jul 11.
2
Bactericidal activity of bacteriophage endolysin HY-133 against Staphylococcus aureus in comparison to other antibiotics as determined by minimum bactericidal concentrations and time-kill analysis.通过最低杀菌浓度和时间杀菌分析确定噬菌体溶菌酶HY-133与其他抗生素相比对金黄色葡萄球菌的杀菌活性。
Diagn Microbiol Infect Dis. 2019 Apr;93(4):362-368. doi: 10.1016/j.diagmicrobio.2018.11.005. Epub 2018 Nov 20.
3
The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri.重组噬菌体溶菌酶HY-133对金黄色葡萄球菌复合体的不同非洲克隆谱系（包括施氏葡萄球菌）具有体外活性。
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2551-3. doi: 10.1128/AAC.02859-15. Print 2016 Apr.
4
A Novel Chimeric Endolysin with Antibacterial Activity against Methicillin-Resistant .一种对耐甲氧西林菌具有抗菌活性的新型嵌合内溶素。
Front Cell Infect Microbiol. 2017 Jun 30;7:290. doi: 10.3389/fcimb.2017.00290. eCollection 2017.
5
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.2008 年至 2011 年，美国医院检测到对利奈唑胺、达托霉素或万古霉素敏感性降低的葡萄球菌的抗菌活性。
Antimicrob Agents Chemother. 2013 Jul;57(7):3178-81. doi: 10.1128/AAC.00484-13. Epub 2013 Apr 29.
6
The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.噬菌体K裂解酶LysK与溶葡萄球菌酶协同作用以杀死耐甲氧西林金黄色葡萄球菌（MRSA）。
FEMS Microbiol Lett. 2008 Oct;287(2):185-91. doi: 10.1111/j.1574-6968.2008.01308.x. Epub 2008 Aug 21.
7
Anti-staphylococcal lysin, LSVT-1701, activity: In vitro susceptibility of Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019.抗葡萄球菌溶素LSVT-1701的活性：2002年至2019年收集的来自世界各地的金黄色葡萄球菌和凝固酶阴性葡萄球菌（CoNS）临床分离株的体外敏感性。
Diagn Microbiol Infect Dis. 2021 Nov;101(3):115471. doi: 10.1016/j.diagmicrobio.2021.115471. Epub 2021 Jun 26.
8
The Novel Phage-Derived Antimicrobial Agent HY-133 Is Active against Livestock-Associated Methicillin-Resistant Staphylococcus aureus.新型噬菌体衍生抗菌剂 HY-133 对畜源耐甲氧西林金黄色葡萄球菌具有活性。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00385-18. Print 2018 Jul.
9
Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands.嵌合噬菌体溶菌酶与溶葡萄球菌酶协同作用，杀死乳腺中的乳腺炎致病金黄色葡萄球菌。
Appl Environ Microbiol. 2012 Apr;78(7):2297-305. doi: 10.1128/AEM.07050-11. Epub 2012 Jan 27.
10
Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus.重组噬菌体phi11和phi12溶菌酶对金黄色葡萄球菌全细胞和生物膜的裂解活性。
Appl Environ Microbiol. 2007 Jan;73(1):347-52. doi: 10.1128/AEM.01616-06. Epub 2006 Nov 3.
引用本文的文献
1
[Phage endolysins-a novel class of antibacterial agents with a wide range of applications].[噬菌体溶菌酶——一类具有广泛应用的新型抗菌剂]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 May 6. doi: 10.1007/s00103-025-04059-9.
2
Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications.抗耐药葡萄球菌属的噬菌体衍生内溶素：特性、抗菌活性及近期应用综述
Infect Dis Ther. 2025 Jan;14(1):13-57. doi: 10.1007/s40121-024-01069-z. Epub 2024 Nov 16.
3
The Synergistic and Chimeric Mechanism of Bacteriophage Endolysins: Opportunities for Application in Biotherapeutics, Food, and Health Sectors.噬菌体溶菌酶的协同和嵌合机制：在生物治疗、食品和健康领域的应用机遇
Probiotics Antimicrob Proteins. 2025 Apr;17(2):807-831. doi: 10.1007/s12602-024-10394-1. Epub 2024 Nov 7.
4
Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria.噬菌体溶菌素治疗革兰氏阳性菌感染的潜力。
J Biomed Sci. 2023 Apr 26;30(1):29. doi: 10.1186/s12929-023-00919-1.
5
Influence of NaCl and pH on lysostaphin catalytic activity, cell binding, and bacteriolytic activity.NaCl 和 pH 对溶葡萄球菌酶催化活性、细胞结合和溶菌活性的影响。
Appl Microbiol Biotechnol. 2022 Oct;106(19-20):6519-6534. doi: 10.1007/s00253-022-12173-w. Epub 2022 Sep 16.
6
Exploration of Bacterial Re-Growth as In Vitro Phenomenon Affecting Methods for Analysis of the Antimicrobial Activity of Chimeric Bacteriophage Endolysins.探索细菌再生长作为一种体外现象对嵌合噬菌体溶菌酶抗菌活性分析方法的影响。
Microorganisms. 2022 Feb 15;10(2):445. doi: 10.3390/microorganisms10020445.
7
Development of a Novel Chimeric Endolysin, Lys109 With Enhanced Lytic Activity Against .一种新型嵌合内溶素Lys109的开发，其对……具有增强的裂解活性
Front Microbiol. 2021 Jan 15;11:615887. doi: 10.3389/fmicb.2020.615887. eCollection 2020.
8
Characterization of Clinical MRSA Isolates from Northern Spain and Assessment of Their Susceptibility to Phage-Derived Antimicrobials.西班牙北部临床耐甲氧西林金黄色葡萄球菌（MRSA）分离株的特征分析及其对噬菌体衍生抗菌剂的敏感性评估。
Antibiotics (Basel). 2020 Jul 25;9(8):447. doi: 10.3390/antibiotics9080447.
9
LytU-SH3b fusion protein as a novel and efficient enzybiotic against methicillin-resistant .LytU-SH3b融合蛋白作为一种新型高效的抗耐甲氧西林酶生物制剂。
Mol Biol Res Commun. 2019 Dec;8(4):151-158.
10
Phage Endolysins as Potential Antimicrobials against Multidrug Resistant and : Current Status of Research and Challenges Ahead.噬菌体溶菌酶作为抗多重耐药菌的潜在抗菌剂：研究现状与面临的挑战
Microorganisms. 2019 Mar 18;7(3):84. doi: 10.3390/microorganisms7030084.
本文引用的文献
1
Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.噬菌体溶菌素 SAL-1 和 LysK 的抗菌性能比较。
Antimicrob Agents Chemother. 2011 Apr;55(4):1764-7. doi: 10.1128/AAC.01097-10. Epub 2011 Jan 24.
2
Inhibition of the activity of both domains of lysostaphin through peptidoglycan modification by the lysostaphin immunity protein.通过溶葡萄球菌素免疫蛋白对肽聚糖进行修饰，抑制溶葡萄球菌素两个结构域的活性。
Appl Environ Microbiol. 2010 Oct;76(20):6944-6. doi: 10.1128/AEM.01066-10. Epub 2010 Aug 20.
3
Bacteriophage-resistant Staphylococcus aureus mutant confers broad immunity against staphylococcal infection in mice.抗噬菌体金黄色葡萄球菌突变体能赋予小鼠对金黄色葡萄球菌感染的广泛免疫力。
PLoS One. 2010 Jul 22;5(7):e11720. doi: 10.1371/journal.pone.0011720.
4
Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens.噬菌体溶菌素：一种新型抗感染药物，可控制革兰氏阳性病原体。
Int J Med Microbiol. 2010 Aug;300(6):357-62. doi: 10.1016/j.ijmm.2010.04.002. Epub 2010 May 10.
5
A poke into the diversity and associations within human anterior nare microbial communities.探究人类前鼻腔微生物群落的多样性及其关联。
ISME J. 2010 Jul;4(7):839-51. doi: 10.1038/ismej.2010.15. Epub 2010 Feb 25.
6
Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.左氟沙星年度效价和光谱评估计划：利奈唑胺监测计划 2008 年结果。
Diagn Microbiol Infect Dis. 2009 Dec;65(4):404-13. doi: 10.1016/j.diagmicrobio.2009.10.001.
7
Mupirocin resistance.莫匹罗星耐药性
Clin Infect Dis. 2009 Sep 15;49(6):935-41. doi: 10.1086/605495.
8
Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects.用莫匹罗星进行金黄色葡萄球菌的鼻腔去定植：优势、劣势及未来前景
J Antimicrob Chemother. 2009 Jul;64(1):9-15. doi: 10.1093/jac/dkp159. Epub 2009 May 18.
9
Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review.耐甲氧西林金黄色葡萄球菌携带的根除：一项系统评价
Clin Infect Dis. 2009 Apr 1;48(7):922-30. doi: 10.1086/597291.
10
Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers.莫匹罗星软膏预防鼻腔携带者金黄色葡萄球菌感染
Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD006216. doi: 10.1002/14651858.CD006216.pub2.
Zotero 插件